German chemical and pharmaceutical company Bayer AG (BAYN.XE) and Onyx Pharmaceuticals Inc. (ONXX) said Friday they are starting a phase III trial of Nexavar (sorafenib) tablets in patients with non-responsive thyroid cancer.

MAIN FACTS:

-Around 400 thyroid cancer patients with no prior systemic therapy will enroll in a randomized, placebo-controlled study.

-The study's endpoint is progression-free survival, as well as overall survival, time to progression and response rate.

-Nexavar is an oral anti-cancer therapy approved in more than 80 countries for liver cancer, and in more than 90 countries for patients with advanced kidney cancer.

 
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.